About

Biography

Dr. Erickson has worked to obtain continuous federal, foundation, internal, and industry funding supporting his and his collaborators' research over the last 10 ten years of his career. He is the inventor or co-inventor on many patents focused on translational treatment development in neurodevelopmental disorders that are held at Cincinnati Children's Hospital Medical Center and at his previous employer the Indiana University School of Medicine. He is considered an international expert in the clinical treatment of fragile X syndrome and has similar expertise in fragile X-specific clinical trial development. Dr. Erickson is additionally an avid teacher of future generations of child psychiatrists has received several teaching awards for his work in physician education. He also enjoys mentoring junior faculty in the behavioral and developmental neuropsychiatry sub-field of child psychiatry.

Specifically in research, he and his colleagues have moved forward several repurposed molecules for study in fragile X syndrome and autism spectrum disorder including work with acamprosate, riluzole, ketamine, D cycloserine, and N acetyl cysteine among other repurposed molecules. He also is working now to move several novel molecules into autism and fragile X-specific study using proprietary compounds abandoned from initially intended use that may hold promise in the disorders which he and his colleagues study.

Insurance Information

Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.

View Insurance Information

Publications

Using head-mounted eye tracking to examine visual and manual exploration during naturalistic toy play in children with and without autism spectrum disorder. Yurkovic, JR; Lisandrelli, G; Shaffer, RC; Dominick, KC; Pedapati, EV; Erickson, CA; Kennedy, DP; Yu, C. Scientific Reports. 2021; 11.

Decades of Progress in the Psychopharmacology of Autism Spectrum Disorder. Henneberry, E; Lamy, M; Dominick, KC; Erickson, CA. Journal of Autism and Developmental Disorders. 2021; 51:4370-4394.

Sex differences in resting EEG power in Fragile X Syndrome. Smith, EG; Pedapati, EV; Liu, R; Schmitt, LM; Dominick, KC; Shaffer, RC; Sweeney, JA; Erickson, CA. Journal of Psychiatric Research. 2021; 138:89-95.

GABAA Alpha 2,3 Modulation Improves Select Phenotypes in a Mouse Model of Fragile X Syndrome. Schaefer, TL; Ashworth, AA; Tiwari, D; Tomasek, MP; Parkins, EV; White, AR; Snider, A; Davenport, MH; Grainger, LM; Becker, RA; et al. Frontiers in Psychiatry. 2021; 12.

Brief Report: Intranasal Ketamine in Adolescents and Young Adults with Autism Spectrum Disorder-Initial Results of a Randomized, Controlled, Crossover, Pilot Study. Wink, LK; Reisinger, DL; Horn, P; Shaffer, RC; O'Brien, K; Schmitt, L; Dominick, KR; Pedapati, EV; Erickson, CA. Journal of Autism and Developmental Disorders. 2021; 51:1392-1399.

Clomipramine. Early, M; Doyle, CA; Wink, L; Erickson, CA; McDougle, CJ. Encyclopedia of Autism Spectrum Disorders. 2021.

Quetiapine. Early, M; Wink, L; Erickson, CA; McDougle, CJ. Encyclopedia of Autism Spectrum Disorders. 2021.

Serotonin Syndrome. Early, M; Wink, L; Erickson, CA; McDougle, CJ. Encyclopedia of Autism Spectrum Disorders. 2021.

Nortriptyline. Early, M; Wink, L; Erickson, CA; McDougle, CJ. Encyclopedia of Autism Spectrum Disorders. 2021.

Atypical Antipsychotics. Early, M; Wink, L; Erickson, CA; McDougle, CJ. Encyclopedia of Autism Spectrum Disorders. 2021.

Patient Ratings and Comments

All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent patient satisfaction company, NRC Health. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey